You are here:

Archived: abiraterone (Zytiga)

Advice

Following a full submission

abiraterone acetate 250mg tablets (Zytiga®) is not recommended for use within NHS Scotland.

Indication under review: with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Abiraterone plus prednisone was associated with significantly improved overall survival compared with placebo plus prednisone in patients with mCRPC previously treated with docetaxel.

The submitting company’s justification of the treatment’s costs in relation to its health benefits was not sufficient to gain acceptance by SMC. In addition, the submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
 

Drug Details

Drug Name: abiraterone (Zytiga)
SMC Drug ID: 764/12
Manufacturer: Janssen-Cilag Ltd
Indication: for the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
BNF Category:
Sub Category: 8.3 Sex hormones and hormone antagonists in malignant disease
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 12 March 2012

Current Advice

Resubmission 13 August 2012

Back